SHC Youngstown Ohio Laboratory Services Company LLC
SHC Youngstown Ohio Laboratory Services Company LLC was paid $3.41M by Medicaid between Jan 2018 and Feb 2024, across 146 billing codes. Its largest line is 82306, Vitamin D; 25 hydroxy, includes fraction(s), if performed — 9.4% of everything it billed.
POLAND, OH 44514
Next to other Clinical Medical Laboratory providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 59,968 | $490K | |
| 2019 | 79,665 | $694K | |
| 2020 | 78,331 | $710K | |
| 2021 | 75,325 | $642K | |
| 2022 | 68,720 | $463K | |
| 2023 | 53,121 | $362K | |
| 2024incomplete | 8,485 | $52K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 9.4% | 19,768 | 18,886 | $320K |
| 80053 | Comprehensive metabolic panel | 8.4% | 44,376 | 40,256 | $288K |
| 80061 | Lipid panel | 7.3% | 30,559 | 29,329 | $249K |
| 84443 | Thyroid stimulating hormone (TSH) | 6.7% | 23,817 | 22,655 | $227K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.6% | 39,229 | 34,666 | $191K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.6% | 7,068 | 6,780 | $190K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.4% | 7,062 | 6,768 | $186K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.2% | 2,489 | 1,270 | $143K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.6% | 22,458 | 21,526 | $124K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.7% | 2,810 | 2,438 | $93K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.6% | 3,621 | 3,531 | $90K |
| 80050 | General health panel | 2.5% | 4,628 | 4,451 | $85K |
134 more codes
| 82607 | 2.1% | 8,644 | $73K | |
| 84439 | 2.1% | 12,585 | $71K | |
| 88142 | 2.0% | 4,857 | $70K | |
| 36415 | Collection of venous blood by venipuncture | 1.7% | 35,616 | $59K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.5% | 10,692 | $50K |
| 82746 | 1.3% | 5,742 | $46K | |
| 87660 | 1.2% | 2,786 | $42K | |
| 87480 | 1.2% | 2,788 | $42K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.2% | 2,305 | $40K |
| 82728 | <1% | 4,204 | $34K | |
| 87510 | <1% | 2,571 | $34K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,818 | $33K |
| 85027 | <1% | 8,999 | $28K | |
| 84153 | <1% | 2,296 | $28K | |
| 80074 | <1% | 1,273 | $25K | |
| 87186 | <1% | 4,783 | $25K | |
| 84403 | <1% | 1,369 | $24K | |
| 83735 | <1% | 5,194 | $21K | |
| 84481 | <1% | 1,789 | $20K | |
| 83540 | <1% | 4,814 | $19K | |
| 83550 | <1% | 3,664 | $19K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,072 | $18K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,697 | $18K |
| 87070 | <1% | 2,988 | $17K | |
| 81513 | <1% | 177 | $15K | |
| 84402 | <1% | 851 | $15K | |
| 80076 | <1% | 2,641 | $14K | |
| 82043 | <1% | 3,631 | $13K | |
| 87077 | <1% | 2,419 | $13K | |
| 84702 | <1% | 1,363 | $13K | |
| 82570 | <1% | 3,856 | $12K | |
| 83090 | <1% | 1,329 | $12K | |
| 86038 | <1% | 1,430 | $12K | |
| 87081 | <1% | 2,414 | $12K | |
| 83970 | <1% | 565 | $12K | |
| 86140 | <1% | 4,087 | $11K | |
| 87590 | <1% | 581 | $10K | |
| 81001 | <1% | 4,824 | $9K | |
| 86803 | <1% | 1,062 | $9K | |
| 84550 | <1% | 3,004 | $8K | |
| 88108 | <1% | 367 | $8K | |
| 85652 | <1% | 4,702 | $8K | |
| 86780 | <1% | 914 | $8K | |
| 87088 | <1% | 1,756 | $8K | |
| 87205 | <1% | 2,434 | $7K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 205 | $6K |
| 87147 | <1% | 1,547 | $6K | |
| 82565 | <1% | 1,668 | $6K | |
| 86769 | <1% | 156 | $6K | |
| 84100 | <1% | 2,118 | $5K | |
| 83690 | <1% | 1,141 | $5K | |
| 87808 | <1% | 483 | $5K | |
| 85610 | <1% | 2,883 | $5K | |
| 82150 | <1% | 1,009 | $4K | |
| 86003 | <1% | 48 | $4K | |
| 87340 | <1% | 741 | $4K | |
| 86762 | <1% | 455 | $4K | |
| 83001 | <1% | 288 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 139 | $4K |
| 86787 | <1% | 332 | $4K | |
| 86430 | <1% | 881 | $4K | |
| 85007 | <1% | 1,890 | $4K | |
| 84146 | <1% | 239 | $3K | |
| 88112 | <1% | 144 | $3K | |
| 84466 | <1% | 459 | $3K | |
| 81003 | <1% | 2,131 | $3K | |
| 84520 | <1% | 1,137 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 102 | $3K |
| 83516 | <1% | 155 | $3K | |
| 87481 | <1% | 176 | $3K | |
| 84480 | <1% | 273 | $3K | |
| 83880 | <1% | 142 | $3K | |
| 84436 | <1% | 566 | $3K | |
| 82248 | <1% | 720 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 141 | $2K |
| 83721 | <1% | 808 | $2K | |
| 83002 | <1% | 148 | $2K | |
| 82550 | <1% | 481 | $2K | |
| 86592 | <1% | 561 | $2K | |
| 83021 | <1% | 131 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 38 | $1K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 38 | $1K |
| 80164 | <1% | 153 | $1K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 61 | $1K |
| 82784 | <1% | 116 | $1K | |
| 86709 | <1% | 166 | $1K | |
| 86705 | <1% | 156 | $1K | |
| 86376 | <1% | 82 | $816.39 | |
| 86480 | <1% | 30 | $736.84 | |
| 84703 | <1% | 139 | $701.73 | |
| 86850 | <1% | 182 | $642.09 | |
| 82731 | <1% | 12 | $628.04 | |
| 86706 | <1% | 85 | $579.45 | |
| 84484 | <1% | 100 | $560.48 | |
| 86593 | <1% | 203 | $530.35 | |
| 82670 | <1% | 27 | $518.65 | |
| 85651 | <1% | 222 | $454.97 | |
| 86901 | <1% | 251 | $426.02 | |
| 86900 | <1% | 249 | $424.42 | |
| 87075 | <1% | 72 | $418.47 | |
| 87625 | <1% | 27 | $418.14 | |
| 86364 | <1% | 26 | $372.77 | |
| 80184 | <1% | 77 | $332.49 | |
| 82785 | <1% | 27 | $330.68 | |
| 87493 | <1% | 16 | $289.88 | |
| 86141 | <1% | 30 | $256.11 | |
| 85730 | <1% | 92 | $241.71 | |
| 87285 | <1% | 20 | $211.47 | |
| 86200 | <1% | 26 | $209.44 | |
| 82977 | <1% | 39 | $204.02 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 672 | $201.68 |
| 84156 | <1% | 81 | $184.86 | |
| 82140 | <1% | 20 | $165.75 | |
| 85045 | <1% | 55 | $164.28 | |
| 82247 | <1% | 41 | $160.72 | |
| 82330 | <1% | 17 | $149.52 | |
| 82105 | <1% | 12 | $133.45 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,121 | $127.19 |
| 86735 | <1% | 13 | $126.20 | |
| 86765 | <1% | 12 | $113.75 | |
| 83020 | <1% | 14 | $112.42 | |
| 87335 | <1% | 13 | $107.29 | |
| 84478 | <1% | 29 | $103.20 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 114 | $94.26 |
| 87045 | <1% | 13 | $84.50 | |
| 86431 | <1% | 14 | $76.21 | |
| 84132 | <1% | 31 | $76.15 | |
| 85018 | <1% | 58 | $48.01 | |
| 85014 | <1% | 37 | $33.04 | |
| 80051 | <1% | 40 | $26.48 | |
| 3046F | 0% | 254 | $0.00 | |
| 3051F | 0% | 460 | $0.00 | |
| 3044F | 0% | 3,263 | $0.00 | |
| 3052F | 0% | 133 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Steward ST. Annes Hospital Corporation | Fall River, MA | $82.71M |
| Steward Trumbull Memorial Hospital, INC. | Warren, OH | $16.49M |
| Steward Sharon Regional Health System, INC. | Sharon, PA | $6.76M |
| Steward Rockledge Hospital, INC. | Rockledge, FL | $6.16M |
| Southwest General Hospital LP | San Antonio, TX | $5.84M |
| Steward Sharon Regional Health System, INC. | Sharon, PA | $5.84M |
| Steward Melbourne Hospital, INC. | Melbourne, FL | $3.35M |
| Steward Hillside Rehabilitation Hospital, INC. | Warren, OH | $2.74M |
| Steward Sebastian River Medical Center, INC. | Sebastian, FL | $2.16M |
| Steward Northside Medical Center, INC. | Youngstown, OH | $1.58M |
| Steward Rockledge Hospital, INC. | Rockledge, FL | $974K |
| Newberry County EMS | Newberry, SC | $758K |
| Steward Sharon Regional Health System, INC. | Mercer, PA | $181K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.